Semaglutide Body Composition: Fat Loss vs Muscle Loss
Semaglutide for Weight Loss
39:61 lean:fat ratio
In the STEP 1 DXA substudy, approximately 39% of semaglutide-induced weight loss was lean mass and 61% was fat mass, but the lean-to-fat mass ratio actually improved because fat loss was disproportionately greater.
Kosiborod et al., STEP 1 Body Composition Analysis, 2021
Kosiborod et al., STEP 1 Body Composition Analysis, 2021
View as imageThe fear is straightforward: you lose weight on semaglutide, but the weight you lose includes muscle. The concern has been amplified by social media posts showing sagging skin and gaunt faces, terms like "Ozempic face" and "Ozempic butt" entering the popular vocabulary. The reality, documented in DXA body composition data from the STEP clinical trials and prospective studies, is more nuanced than either the alarmist headlines or the dismissive rebuttals suggest. Semaglutide does cause lean mass loss. Every form of weight loss does. The question is whether semaglutide causes disproportionate lean mass loss compared to other weight loss methods, whether the lean mass loss is clinically meaningful, and what can be done about it. The data on these questions has matured substantially, with the 2026 SEMALEAN study providing the most detailed prospective body composition analysis to date.[1] For broader context on semaglutide for weight loss, see the pillar article.
Key Takeaways
- In the STEP 1 DXA substudy, semaglutide reduced total fat mass by 19.3%, visceral fat by 27.4%, and lean body mass by 9.7%, but the proportion of lean mass relative to total body mass increased by 3.0 percentage points
- The SEMALEAN study found lean mass declined by 3 kg at 7 months but stabilized thereafter, while fat mass continued to decline through 12 months (Alissou et al., Diabetes Obesity Metabolism, 2026)[1]
- Lean mass loss comprised 26-40% of total weight loss across GLP-1 agonist trials, which is comparable to the 25-35% lean mass loss seen with caloric restriction and bariatric surgery
- The Phase 2 COURAGE trial found that combining semaglutide with muscle-preserving antibodies spared 50-80% of the lean mass lost with semaglutide alone
- A case series showed that patients combining GLP-1 therapy with resistance training and high protein intake limited lean mass loss to 6.9% of weight lost, with two patients gaining lean mass while losing fat
- Pharmacologic approaches to preserving lean mass during GLP-1-induced weight loss are an active area of development (Arora et al., J Clin Med, 2026)[3]
The STEP 1 Body Composition Data
The foundational body composition data comes from a DXA substudy within the STEP 1 trial, which randomized 1,961 adults with obesity (BMI 30 or above, or 27 or above with a weight-related comorbidity) to semaglutide 2.4 mg weekly or placebo for 68 weeks.
The headline numbers:
- Mean weight loss: 15.0% with semaglutide versus 3.6% with placebo
- Total fat mass reduction: 19.3%
- Visceral fat mass reduction: 27.4%
- Total lean body mass reduction: 9.7%
The lean mass number generates anxiety, but context changes its interpretation. Of the total weight lost, approximately 61% was fat mass and 39% was lean mass. This ratio is within the normal range for any form of significant weight loss. Studies of caloric restriction consistently show 25-35% of weight loss coming from lean tissue; bariatric surgery shows 20-35%. Semaglutide's 39% is at the higher end of this range but not clearly outside it.
The ratio matters more than the absolute numbers. Despite losing lean mass in absolute terms, patients on semaglutide saw their lean-to-fat mass ratio improve. The proportion of lean body mass relative to total body mass increased by 3.0 percentage points. In other words, patients ended up with a body that was proportionally leaner, even though they had less total lean tissue.
Visceral fat loss was disproportionately large at 27.4%, nearly triple the lean mass reduction. Visceral fat is the metabolically active, inflammation-promoting fat depot associated with insulin resistance, cardiovascular disease, and metabolic syndrome. Preferential loss of visceral fat is a favorable body composition outcome. Abel et al. (2026) described the molecular mechanisms underlying semaglutide-mediated adipose tissue remodeling, showing that GLP-1 receptor activation influences adipocyte lipolysis, brown fat activation, and inflammatory signaling pathways beyond simple caloric deficit.[4]
The SEMALEAN Study: What Happens Over Time
The STEP 1 DXA data captured a single time point (week 68). The SEMALEAN study, published in 2026 by Alissou et al., provided prospective body composition measurements at baseline, 7 months, and 12 months in 115 patients with obesity starting semaglutide.[1]
Key findings:
- Weight loss: 10% at 7 months, 13% at 12 months
- Total fat mass: decreased 14% at 7 months and 18% at 12 months
- Lean mass: decreased by approximately 3 kg at 7 months but then stabilized between 7 and 12 months
- Handgrip strength: maintained throughout the study
- 59% of patients achieved 10% or greater weight loss
The lean mass stabilization finding is the most clinically relevant result. Early lean mass loss appears to be a transient adaptation to the rapid caloric deficit that semaglutide creates, particularly in the first months when appetite suppression is strongest and patients are often eating substantially less than before. As the body adapts and weight loss slows, lean mass loss stops while fat mass continues to decline.
The handgrip strength preservation is equally important. Lean mass loss without functional impairment suggests that the lost "lean mass" on DXA may include substantial amounts of water, glycogen, and non-contractile tissue rather than pure skeletal muscle protein. DXA measures lean soft tissue, which includes water-containing organs, blood volume, and intracellular water. Rapid weight loss reduces glycogen stores (each gram of glycogen binds approximately 3 grams of water), which appears as lean mass loss on DXA without reflecting actual muscle protein breakdown.
How Much Muscle Are You Actually Losing?
The distinction between DXA-measured "lean mass" and actual skeletal muscle is critical for interpreting body composition studies.
DXA lean mass includes:
- Skeletal muscle (the contractile tissue people worry about)
- Organ mass (liver, kidneys, heart, etc.)
- Blood volume and plasma
- Intracellular water and glycogen
- Connective tissue
When a patient loses 15% of body weight, several of these non-muscle lean mass components decrease naturally. A smaller body requires less blood volume. A smaller liver stores less glycogen. Reduced caloric intake depletes muscle glycogen and its associated water. These changes register as lean mass loss on DXA without reflecting sarcopenia (pathological muscle loss).
The COURAGE trial (Regeneron, Phase 2) attempted to quantify this. They found that approximately 35% of semaglutide-induced weight loss was lean mass on DXA, but combining semaglutide with trevogrumab (an anti-activin A antibody) or garetosmab (an anti-activin A antibody) spared 50-80% of this lean mass while increasing fat loss. This suggests that a substantial portion of the lean mass loss during semaglutide treatment is modifiable, meaning it represents muscle that can be preserved with the right intervention rather than inevitable water and glycogen redistribution.
Exercise and Protein: The Evidence for Lean Mass Preservation
The most practical question is whether lifestyle interventions can preserve lean mass during GLP-1 therapy. A 2025 case series documented three patients combining GLP-1 therapy (semaglutide or tirzepatide) with intentional resistance training and high protein intake:
- Patient 1: Lost 33.0% body weight, 53.4% fat mass, and only 6.9% lean mass (vs. 26-40% lean mass loss in typical trials)
- Patient 2: Lost 26.8% body weight, 61.6% fat mass, and gained 2.5% lean mass
- Patient 3: Lost 13.2% body weight, 46.9% fat mass, and gained 5.8% lean mass
Two of three patients gained lean mass while losing substantial amounts of fat, a body recomposition outcome that is rare during weight loss without pharmacological assistance. The key factors: regular resistance training (3-4 sessions per week) and protein intake above 1.2 g/kg/day.
These are case reports, not randomized trials, and the sample size is three. But they align with exercise physiology principles: resistance training provides the mechanical stimulus for muscle protein synthesis, and adequate protein provides the substrate. If both are present, muscle can be maintained or even built during a caloric deficit, particularly in individuals with obesity who have significant room for body recomposition.
Aimelet et al. (2026) reviewed the broader pharmacological landscape for preserving lean mass during weight loss, including GLP-1 combinations with myostatin inhibitors, activin receptor antibodies, and growth hormone secretagogues. They concluded that the challenge is real but solvable, with multiple pharmacological and lifestyle approaches showing promise.[2]
How Semaglutide Compares to Other Weight Loss Methods
The lean mass loss concern is not unique to semaglutide. Every form of energy deficit causes some lean mass loss:
| Method | Typical lean mass as % of weight lost |
|---|---|
| Caloric restriction alone | 25-35% |
| Bariatric surgery (sleeve/bypass) | 20-35% |
| Very low calorie diet (VLCD) | 30-40% |
| Semaglutide 2.4 mg | 26-39% |
| Tirzepatide | 25-35% |
| Caloric restriction + resistance training | 15-25% |
Semaglutide's lean mass loss is comparable to other methods that produce similar weight loss magnitudes. The concern is proportional to the weight loss: semaglutide produces 15-17% weight loss (more than most diets but less than surgery), and the lean mass loss tracks accordingly.
The comparison with bariatric surgery is particularly relevant. Sleeve gastrectomy and Roux-en-Y gastric bypass produce 25-35% weight loss, with 20-35% of that being lean mass. Nobody calls this "surgery muscle," and surgical patients rarely receive the same scrutiny about body composition. The framing around semaglutide reflects the novelty of pharmaceutical weight loss at this magnitude more than a unique biological problem.
For a discussion of the specific risks of lean mass loss in older adults on GLP-1 therapy, see the dedicated article. The sarcopenia concern is most clinically relevant in patients over 65, who have lower baseline muscle reserves and slower recovery from muscle loss.
The Weight Regain Body Composition Question
When patients stop semaglutide, weight regain is well documented. Wilding et al. (2022) showed that patients regained approximately two-thirds of lost weight within one year of discontinuing semaglutide in the STEP 1 extension.[5]
The body composition of regained weight is a critical concern. Weight regain after diet-induced weight loss typically has a higher fat-to-lean ratio than the original weight loss. If a patient loses 15 kg (6 kg lean, 9 kg fat) and regains 10 kg (2 kg lean, 8 kg fat), they end up with less muscle and more fat than before they started. This "weight cycling" effect has been documented in the diet literature, though long-term body composition data after semaglutide discontinuation remains limited.
Chen et al. (2026) compared weight regain patterns after lifestyle intervention, bariatric surgery, and semaglutide. All three groups showed weight regain after cessation of the intervention, but the body composition of regained weight differed by method and by the presence or absence of exercise during the weight loss phase.[6]
Pharmacological Muscle Preservation: What Is in Development
The pharmaceutical industry has recognized lean mass preservation as a clinical opportunity. Several approaches are in clinical trials:
Myostatin/activin pathway inhibitors: The COURAGE trial combines semaglutide with trevogrumab (anti-activin A) or garetosmab. Interim results show 50-80% lean mass preservation compared to semaglutide alone. These biologics block the signals that promote muscle wasting during caloric deficit.
Growth hormone secretagogues: Tesamorelin, a GHRH analog, has shown body composition benefits including fat loss with lean mass preservation in HIV-associated lipodystrophy. Badran et al. (2026) reported that tesamorelin reduced hepatic fat while preserving lean body mass, a combination relevant to obesity treatment.[7]
Bimagrumab: An anti-activin type II receptor antibody that has been tested in combination with semaglutide. Early data suggests it can promote muscle gain during weight loss.
Arora et al. (2026) comprehensively reviewed the pharmacologic treatment landscape for lean body mass preservation during weight loss, cataloging every agent in development and assessing the strength of evidence for each approach.[3]
The convergence of GLP-1 agonists with muscle-preserving agents represents a new treatment paradigm: precision body composition management rather than crude weight reduction. For how tirzepatide compares on body composition, including its dual GIP/GLP-1 mechanism, see the dedicated article. For information on what happens when semaglutide is stopped, including body composition changes during regain, see the discontinuation article. The dose escalation approach may also be relevant, as slower titration could theoretically allow more time for body composition adaptation.
The Practical Takeaway
The body composition data supports several conclusions:
Semaglutide does cause lean mass loss. This is real, measurable by DXA, and proportional to the magnitude of weight loss.
The lean mass loss is not disproportionate compared to other methods that produce similar weight loss. It falls within the range seen with caloric restriction and bariatric surgery.
Lean mass loss stabilizes over time. The SEMALEAN data shows that lean mass stops declining after approximately 7 months, while fat loss continues.
Functional measures are preserved. Handgrip strength, the most clinically relevant measure of sarcopenia risk, was maintained in the SEMALEAN study.
The fat loss composition is favorable. Visceral fat loss is disproportionately large, improving metabolic health markers beyond what total weight loss alone would predict. Understanding how much weight semaglutide produces helps contextualize these body composition changes.
Exercise and protein dramatically improve outcomes. Resistance training and adequate protein intake can shift the composition of weight loss from 39% lean (typical semaglutide) to under 10% lean or even achieve lean mass gain during fat loss.
The Bottom Line
Semaglutide changes body composition in a pattern that is broadly comparable to other methods of significant weight loss. In the STEP 1 DXA substudy, fat mass declined 19.3% and lean mass declined 9.7%, with visceral fat showing the largest reduction at 27.4%. The SEMALEAN study found lean mass stabilized after 7 months while fat continued to decline. Approximately 26-39% of semaglutide-induced weight loss is lean mass on DXA, but this includes water, glycogen, and organ mass alongside skeletal muscle. Handgrip strength was preserved throughout. Resistance training and high protein intake can reduce lean mass loss to under 10% of total weight lost, and pharmacological muscle-preserving agents are in advanced clinical trials.